Cargando…

Investigating the response scale of the EORTC QLQ-C30 in German cancer patients and a population survey

BACKGROUND: The European Organization for research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) scales are scored on a 4-point response scale, ranging from not at all to very much. Previous studies have shown that the German translation of the response option quite a...

Descripción completa

Detalles Bibliográficos
Autores principales: Koller, Michael, Müller, Karolina, Nolte, Sandra, Schmidt, Heike, Harvey, Christina, Mölle, Ulrike, Boehm, Andreas, Engeler, Daniel, Metzger, Jürg, Sztankay, Monika, Holzner, Bernhard, Groenvold, Mogens, Kuliś, Dagmara, Bottomley, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501673/
https://www.ncbi.nlm.nih.gov/pubmed/34625074
http://dx.doi.org/10.1186/s12955-021-01866-x
_version_ 1784580734589075456
author Koller, Michael
Müller, Karolina
Nolte, Sandra
Schmidt, Heike
Harvey, Christina
Mölle, Ulrike
Boehm, Andreas
Engeler, Daniel
Metzger, Jürg
Sztankay, Monika
Holzner, Bernhard
Groenvold, Mogens
Kuliś, Dagmara
Bottomley, Andrew
author_facet Koller, Michael
Müller, Karolina
Nolte, Sandra
Schmidt, Heike
Harvey, Christina
Mölle, Ulrike
Boehm, Andreas
Engeler, Daniel
Metzger, Jürg
Sztankay, Monika
Holzner, Bernhard
Groenvold, Mogens
Kuliś, Dagmara
Bottomley, Andrew
author_sort Koller, Michael
collection PubMed
description BACKGROUND: The European Organization for research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) scales are scored on a 4-point response scale, ranging from not at all to very much. Previous studies have shown that the German translation of the response option quite a bit as mäßig violates interval scale assumptions, and that ziemlich is a more appropriate translation. The present studies investigated differences between the two questionnaire versions. METHODS: The first study employed a balanced cross-over design and included 450 patients with different types of cancer from three German-speaking countries. The second study was a representative survey in Germany including 2033 respondents. The main analyses included compared the ziemlich and mäßig version of the questionnaire using analyses of covariance adjusted for sex, age, and health burden. RESULTS: In accordance with our hypothesis, the adjusted summary score was lower in the mäßig than in the ziemlich version; Study 1: − 4.5 (95% CI − 7.8 to − 1.3), p = 0.006, Study 2: − 3.1 (95% CI − 4.6 to − 1.5), p < 0.001. In both studies, this effect was pronounced in respondents with a higher health burden; Study 1: − 6.8 (95% CI − 12.2 to − 1.4), p = 0.013; Study 2: − 4.5 (95% CI − 7.3 to − 1.7), p = 0.002. CONCLUSIONS: We found subtle but consistent differences between the two questionnaire versions. We recommend to use the optimized response option for the EORTC QLQ-C30 as well as for all other German modules. Trial registration: The study was retrospectively registered on the German Registry for Clinical Studies (reference number DRKS00012759, 04th August 2017, https://www.drks.de/DRKS00012759). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12955-021-01866-x.
format Online
Article
Text
id pubmed-8501673
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85016732021-10-20 Investigating the response scale of the EORTC QLQ-C30 in German cancer patients and a population survey Koller, Michael Müller, Karolina Nolte, Sandra Schmidt, Heike Harvey, Christina Mölle, Ulrike Boehm, Andreas Engeler, Daniel Metzger, Jürg Sztankay, Monika Holzner, Bernhard Groenvold, Mogens Kuliś, Dagmara Bottomley, Andrew Health Qual Life Outcomes Research BACKGROUND: The European Organization for research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) scales are scored on a 4-point response scale, ranging from not at all to very much. Previous studies have shown that the German translation of the response option quite a bit as mäßig violates interval scale assumptions, and that ziemlich is a more appropriate translation. The present studies investigated differences between the two questionnaire versions. METHODS: The first study employed a balanced cross-over design and included 450 patients with different types of cancer from three German-speaking countries. The second study was a representative survey in Germany including 2033 respondents. The main analyses included compared the ziemlich and mäßig version of the questionnaire using analyses of covariance adjusted for sex, age, and health burden. RESULTS: In accordance with our hypothesis, the adjusted summary score was lower in the mäßig than in the ziemlich version; Study 1: − 4.5 (95% CI − 7.8 to − 1.3), p = 0.006, Study 2: − 3.1 (95% CI − 4.6 to − 1.5), p < 0.001. In both studies, this effect was pronounced in respondents with a higher health burden; Study 1: − 6.8 (95% CI − 12.2 to − 1.4), p = 0.013; Study 2: − 4.5 (95% CI − 7.3 to − 1.7), p = 0.002. CONCLUSIONS: We found subtle but consistent differences between the two questionnaire versions. We recommend to use the optimized response option for the EORTC QLQ-C30 as well as for all other German modules. Trial registration: The study was retrospectively registered on the German Registry for Clinical Studies (reference number DRKS00012759, 04th August 2017, https://www.drks.de/DRKS00012759). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12955-021-01866-x. BioMed Central 2021-10-09 /pmc/articles/PMC8501673/ /pubmed/34625074 http://dx.doi.org/10.1186/s12955-021-01866-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Koller, Michael
Müller, Karolina
Nolte, Sandra
Schmidt, Heike
Harvey, Christina
Mölle, Ulrike
Boehm, Andreas
Engeler, Daniel
Metzger, Jürg
Sztankay, Monika
Holzner, Bernhard
Groenvold, Mogens
Kuliś, Dagmara
Bottomley, Andrew
Investigating the response scale of the EORTC QLQ-C30 in German cancer patients and a population survey
title Investigating the response scale of the EORTC QLQ-C30 in German cancer patients and a population survey
title_full Investigating the response scale of the EORTC QLQ-C30 in German cancer patients and a population survey
title_fullStr Investigating the response scale of the EORTC QLQ-C30 in German cancer patients and a population survey
title_full_unstemmed Investigating the response scale of the EORTC QLQ-C30 in German cancer patients and a population survey
title_short Investigating the response scale of the EORTC QLQ-C30 in German cancer patients and a population survey
title_sort investigating the response scale of the eortc qlq-c30 in german cancer patients and a population survey
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501673/
https://www.ncbi.nlm.nih.gov/pubmed/34625074
http://dx.doi.org/10.1186/s12955-021-01866-x
work_keys_str_mv AT kollermichael investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey
AT mullerkarolina investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey
AT noltesandra investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey
AT schmidtheike investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey
AT harveychristina investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey
AT molleulrike investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey
AT boehmandreas investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey
AT engelerdaniel investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey
AT metzgerjurg investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey
AT sztankaymonika investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey
AT holznerbernhard investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey
AT groenvoldmogens investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey
AT kulisdagmara investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey
AT bottomleyandrew investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey
AT investigatingtheresponsescaleoftheeortcqlqc30ingermancancerpatientsandapopulationsurvey